Compare ENIC & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENIC | IMVT |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | Chile | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.3B |
| IPO Year | 2015 | 2019 |
| Metric | ENIC | IMVT |
|---|---|---|
| Price | $4.19 | $34.23 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 17 |
| Target Price | $4.94 | ★ $48.50 |
| AVG Volume (30 Days) | 544.7K | ★ 1.4M |
| Earning Date | 10-28-2026 | 11-09-2026 |
| Dividend Yield | ★ 4.58% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.31 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $101.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.64 | $21.86 |
| 52 Week High | $4.74 | $45.42 |
| Indicator | ENIC | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 42.01 | 58.40 |
| Support Level | $4.11 | $26.01 |
| Resistance Level | $4.47 | $34.60 |
| Average True Range (ATR) | 0.11 | 1.47 |
| MACD | -0.01 | 0.98 |
| Stochastic Oscillator | 20.84 | 65.41 |
Enel Chile SA is an electricity utility company engaged, through its subsidiaries and affiliates, in the generation, transmission, and distribution of electricity across Chile. The Company operates through two main segments: the Generation Business, which includes companies that own and operate power plants supplying electricity to the grid and generates the majority of revenue; and the Distribution and Network Business, which consists of companies operating under public utility concessions to distribute electricity to end customers.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.